Compare FNUC & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FNUC | IMMP |
|---|---|---|
| Founded | 2018 | 1987 |
| Country | Canada | Australia |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.5M | 58.2M |
| IPO Year | 2021 | 2012 |
| Metric | FNUC | IMMP |
|---|---|---|
| Price | $2.44 | $0.31 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 300.4K | ★ 1.1M |
| Earning Date | 03-26-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $417.85 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.89 | $0.29 |
| 52 Week High | $2.82 | $3.53 |
| Indicator | FNUC | IMMP |
|---|---|---|
| Relative Strength Index (RSI) | 60.37 | 14.38 |
| Support Level | $2.26 | N/A |
| Resistance Level | $2.51 | $0.39 |
| Average True Range (ATR) | 0.23 | 0.02 |
| MACD | 0.01 | 0.08 |
| Stochastic Oscillator | 52.44 | 21.27 |
Frontier Nuclear and Minerals Inc is developing a U.S.-focused front-end nuclear fuel cycle company through a portfolio of U.S. uranium exploration and development projects in Wyoming, Colorado, and Utah, together with investments in next-generation uranium enrichment and small modular reactors. Frontier Nuclear is actively evaluating value-accretive investment opportunities in other sectors of the domestic U.S. nuclear fuel cycle. The group is developing a portfolio of critical minerals projects in America, Canada, and Namibia, including uranium, tantalum, cesium, and lithium. Its projects are Engo Valley, Pine Ridge, Shatford Lake, Snow Lake Lithium, and Tallahassee.
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.